Atractylenolide‐III alleviates osteoarthritis and chondrocyte senescence by targeting NF‐κB signaling
Phytotherapy Research · 2023-10 · 37 (10) · 4607-4620
DOI: 10.1002/ptr.7929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 28.06.2023. Verfasst von Yizhou Xu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Embryology, Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, National Demonstrati…. Hauptthemen laut MEDLINE: Chondrocytes, Osteoarthritis, Sesquiterpenes, NF-kappa B. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Atractylenolide‐III (AT‐III) is well known as its role in antioxidant and anti‐inflammatory. Present study was aimed to figure out its effects on osteoarthritis and potential mechanisms. Rat model, human osteoarthritis cartilage explants as well as rat/human chondrocyte cultures were prepared to test AT‐III's effects on osteoarthritis progression and chondrocyte senescence. Potential targeted molecules of AT‐III were predicted using network pharmacology and molecular docking, assessed by Western blotting and then verified with rescue experiments. AT‐III treatment alleviated osteoarthritis severity (shown by OARSI grading score and micro‐CT) and chondrocyte senescence (indexed by levels of SA‐β‐gal, P16, P53, MMP13, ROS and ratio of healthy/collapsed mitochondrial membrane potentials). Network pharmacology and molecular docking suggested that AT‐III might play role through NF‐κB pathway. Further experiments revealed that AT‐III reduced phosphorylation of IKKα/β, IκBα and P65 in NF‐κB pathway. As well as nuclear translocation of p65. Both in vivo and in vitro experiments indicated that AT‐III's effects on osteoarthritis and anti‐senescence were reversed by an NF‐κB agonist. AT‐III could alleviate osteoarthritis by inhibiting chondrocyte senescence through NF‐κB pathway, which indicated that AT‐III is a prospective drug for osteoarthritis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Histology and Embryology, Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, National Demonstration Center for Experimental Education, School of Basic Medical Sciences…
- Department of Spinal Surgery, Orthopedic Medical Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
- School of Chinese Herbal Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
- Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
ORCID-Profile: Jiasong Guo
Förderung
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Xu, Y., Hu, X., Cai, J., Li, Y., Zou, Y., Wang, Y., Xie, C., Xu, S., Wang, Y., Zheng, Y., Mahamat, D. A., Xu, Y., Wang, X., Li, X., Liu, A., Chen, D., Zhu, L., & Guo, J. (2023). Atractylenolide‐III alleviates osteoarthritis and chondrocyte senescence by targeting NF‐κB signaling. Phytotherapy Research, 37(10), 4607-4620. https://doi.org/10.1002/ptr.7929
Vancouver
Xu Y, Hu X, Cai J, Li Y, Zou Y, Wang Y, et al. Atractylenolide‐III alleviates osteoarthritis and chondrocyte senescence by targeting NF‐κB signaling. Phytotherapy Research. 2023;37(10):4607-4620. doi:10.1002/ptr.7929
BibTeX
@article{Xu2023,
author = {Xu, Yizhou and Hu, Xiaofang and Cai, Jiale and Li, Yunlun and Zou, Ying and Wang, Yihan and Xie, Changnan and Xu, Shuyi and Wang, Yanqing and Zheng, Yuli and Mahamat, Djibril Adam and Xu, Yuantao and Wang, Xianghai and Li, Xican and Liu, Aijun and Chen, Dongfeng and Zhu, Lixin and Guo, Jiasong},
title = {Atractylenolide‐III alleviates osteoarthritis and chondrocyte senescence by targeting NF‐κB signaling},
journal = {Phytotherapy Research},
year = {2023},
volume = {37},
number = {10},
pages = {4607--4620},
doi = {10.1002/ptr.7929}
}
EUVIMED